Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Launched by CHANG GUNG MEMORIAL HOSPITAL · Aug 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain lung cancers stop responding to a common type of treatment called tyrosine kinase inhibitors (TKIs). These drugs work well at first for lung cancers driven by specific gene changes, but over time, the cancer often finds ways to resist the treatment and start growing again. This study aims to better understand the genetic changes and other biological processes that cause this resistance by looking closely at tumor tissue and blood samples from patients who have already been treated with TKIs and whose cancer has gotten worse.

Patients who may be eligible for this study are adults diagnosed with non-small cell lung cancer that has specific gene mutations or fusions, such as EGFR, ALK, ROS1, and several others. They must have received TKI treatment and shown disease progression during that treatment. Participants will provide tumor tissue and blood samples so researchers can analyze the DNA and other genetic information. This study is not yet open for enrollment, but it hopes to uncover new insights that could lead to better treatments for patients whose cancer stops responding to current therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed NSCLC, with at least one of the known oncogene mutation prior to systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation
• • 2. Patient had received tyrosine kinase inhibitor (TKI) with progressive disease, as assessed by the treating physician
• • 3. Had tumor tissue available for DNA extraction and sequencing.
• • 4. Eligible for withdrawal of a blood sample for DNA extraction and sequencing.
• Exclusion Criteria:
• • 1. Patient had not received TKI or did not have documented disease progression during TKI treatment.
• • 2. Tumor tissue was unavailable for DNA extraction or the DNA quality did not meet the sequencing requirement.